OncRef

Clinical Trial: NCT04661007

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Incyte Biosciences Japan GK
Information Provided By:Incyte Corporation
Last Update Posted:2026-10-21

Study Overview

Brief Summary

This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.

Official Title

A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma

Conditions

Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma

Intervention / Treatment

  • Drug: tafasitamab
  • Drug: lenalidomide
  • Drug: parsaclisib
  • Drug: R-CHOP

Other Study ID Numbers

  • INCMOR 0208-102

Start Date (Actual)

2020-12-15

Primary Completion Date (Actual)

2025-07-01

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

72

Study Type

Interventional

Phase

Phase 1, Phase 2